We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes.
By accepting optional cookies, you consent to the processing of your personal data – including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.
See our privacy policy for more information on the use of your personal data.
Manage preferences for further information and to change your choices.
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Purpose of review: To highlight pharmacological and non-pharmacological approaches to reversing hypertensive left ventricular hypertrophy (LVH). We identify high-risk phenotypes that may benefit from aggressive blood pressure (BP) management to prevent incident outcomes such as the development of atherosclerotic cardiovascular disease, stroke, and heart failure.
Recent findings: LVH is a modifiable risk factor. Intensive BP lowering (systolic BP < 120 mmHg) induces greater regression of electrocardiographic LVH than standard BP targets. The optimal agents for inducing LVH regression include renin-angiotensinogen-aldosterone system inhibitors and calcium channel blockers, although recent meta-analyses have demonstrated superior efficacy of non-hydrochlorothiazide diuretics. Novel agents (such as sacubitril/valsartan) and non-pharmacological approaches (like bariatric surgery) hold promise but longitudinal studies assessing their impact on clinical outcomes are needed. LVH regression is achievable with appropriate therapy with first-line antihypertensive agents. Additional studies are warranted to assess if intensive BP lowering in high-risk groups (such as blacks, women, and malignant LVH) improves outcomes.
Keywords: Hypertension; Hypertensive heart disease; Left ventricular hypertrophy; Regression; Remodeling.
how to stay healthy on the inside while looking great on the outside
managing the psychological dependency on being ”on” gear
why i recommend getting a baseline heart scan before your first blast
the truth about ”detox” teas vs actual organ support supplements
how often should you really be getting bloodwork done on cycle
best ways to reduce systemic inflammation while running heavy cycles
Latest Post: Nandrolone Phenylpropionate vs Decanoate (DECA) Benefits Our newest member: Josh Sutton Recent Posts Unread Posts
